Morgan Stanley Vaxxinity, Inc. Transaction History

Morgan Stanley

14 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 Aug 16, 2024	SELL	$0.62 - $0.86 $104,337 - $144,726	-168,287 Reduced 73.0%	62,229 $44,000
Q1 2024 May 15, 2024	SELL	$0.62 - $0.86 $104,337 - $144,726	-168,287 Reduced 73.0%	62,229 $44,000
Q4 2023 Aug 16, 2024	BUY	$0.7 - $1.31 $161,361 - $301,975	230,516 New	230,516 $195,000
Q4 2023 Feb 13, 2024	BUY	$0.7 - $1.31 $135,831 - $254,198	194,045 Added 532.05%	230,516 $195,000
Q3 2023 Nov 15, 2023	SELL	$1.25 - $3.0 $14,787 - $35,490	-11,830 Reduced 24.49%	36,471 $49,000
Q2 2023 Aug 14, 2023	BUY	$1.73 - $2.79 $60,247 - $97,161	34,825 Added 258.42%	48,301 $121,000
Q1 2023 May 15, 2023	BUY	$1.43 - $4.24 $12,798 - $37,948	8,950 Added 197.75%	13,476 $30,000
Q4 2022 Feb 14, 2023	SELL	$1.31 - $2.62 $5,118 - $10,236	-3,907 Reduced 46.33%	4,526 $6,000
Q3 2022 Nov 14, 2022	SELL	$1.64 - $2.48 $4,829 - $7,303	-2,945 Reduced 25.88%	8,433 $16,000
Q2 2022 Oct 27, 2022	BUY	$1.55 - $6.95 $5,519 - $24,748	3,561 Added 45.55%	11,378 $18,000
Q2 2022 Aug 15, 2022	BUY	$1.55 - $6.95 $5,519 - $24,748	3,561 Added 45.55%	11,378 $18,000
Q1 2022 Oct 27, 2022	SELL	$3.7 - $8.6 $13,175 - $30,624	-3,561 Reduced 31.3%	7,817 $34,000
Q1 2022 May 13, 2022	SELL	$3.7 - $8.6 $12,524 - $29,111	-3,385 Reduced 30.22%	7,817 $34,000
Q4 2021 Feb 14, 2022	BUY	$5.55 - $18.46 $62,171 - $206,788	11,202 New	11,202 $63,000

469K

Ticker VAXX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 112,150,000
Market Cap $1.12M
Description
Vaxxinity, Inc., a biotechnology company, focuses on developing product candidates for human use in the fields of neurology and coronaviruses in the United States. The company engages in developing UB-311 that targets toxic forms of aggregated amyloid-b in the brain to fight Alzheimer's disease (AD) that is in phase 2 clinical trial; UB-312 that...

Get notified when there are updates to the investment portfolio of Morgan Stanley, based on Form 13F filings with the SEC.

Stay updated on Morgan Stanley with notifications on news.